ChREBPβ is dispensable for the control of glucose homeostasis and energy balance.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
22 02 2022
Historique:
received: 22 07 2021
accepted: 05 01 2022
pubmed: 19 1 2022
medline: 29 3 2022
entrez: 18 1 2022
Statut: epublish

Résumé

Impaired glucose metabolism is observed in obesity and type 2 diabetes. Glucose controls gene expression through the transcription factor ChREBP in liver and adipose tissues. Mlxipl encodes 2 isoforms: ChREBPα, the full-length form (translocation into the nucleus is under the control of glucose), and ChREBPβ, a constitutively nuclear shorter form. ChREBPβ gene expression in white adipose tissue is strongly associated with insulin sensitivity. Here, we investigated the consequences of ChREBPβ deficiency on insulin action and energy balance. ChREBPβ-deficient male and female C57BL6/J and FVB/N mice were produced using CRISPR/Cas9-mediated gene editing. Unlike global ChREBP deficiency, lack of ChREBPβ showed modest effects on gene expression in adipose tissues and the liver, with variations chiefly observed in brown adipose tissue. In mice fed chow and 2 types of high-fat diets, lack of ChREBPβ had moderate effects on body composition and insulin sensitivity. At thermoneutrality, ChREBPβ deficiency did not prevent the whitening of brown adipose tissue previously reported in total ChREBP-KO mice. These findings revealed that ChREBPβ is dispensable for metabolic adaptations to nutritional and thermic challenges.

Identifiants

pubmed: 35041621
pii: 153431
doi: 10.1172/jci.insight.153431
pmc: PMC8876429
doi:
pii:

Substances chimiques

Basic Helix-Loop-Helix Leucine Zipper Transcription Factors 0
Blood Glucose 0
Mlxipl protein, mouse 0
RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Mol Metab. 2017 Nov;6(11):1381-1394
pubmed: 29107286
Methods Mol Biol. 2016;1438:19-53
pubmed: 27150082
Dis Model Mech. 2010 Mar-Apr;3(3-4):156-66
pubmed: 20212084
Proc Natl Acad Sci U S A. 2004 May 11;101(19):7281-6
pubmed: 15118080
Clin Nutr. 2012 Jun;31(3):386-90
pubmed: 22385730
Hepatology. 2015 Oct;62(4):1086-100
pubmed: 25761756
Cell Rep. 2021 Jan 12;34(2):108624
pubmed: 33440156
Cell Metab. 2017 Aug 1;26(2):324-341
pubmed: 28768172
Diabetes. 2020 Apr;69(4):591-602
pubmed: 31974143
Cell Metab. 2015 Feb 3;21(2):334-347
pubmed: 25651185
N Engl J Med. 2009 Apr 9;360(15):1500-8
pubmed: 19357405
Nat Metab. 2019 Jan;1(1):133-146
pubmed: 32694809
Sci Rep. 2018 Jan 11;8(1):474
pubmed: 29323173
Endocrinology. 2015 Nov;156(11):4008-19
pubmed: 26181104
N Engl J Med. 2009 Apr 9;360(15):1518-25
pubmed: 19357407
Mol Metab. 2016 Sep 30;5(12):1208-1215
pubmed: 27900263
Cell Metab. 2013 Jul 2;18(1):106-17
pubmed: 23823481
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9116-21
pubmed: 11470916
Nat Commun. 2016 Apr 21;7:11365
pubmed: 27098609
Diabetes. 2006 May;55(5):1179-89
pubmed: 16644671
Nature. 2012 Apr 19;484(7394):333-8
pubmed: 22466288
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E358-64
pubmed: 16705063
J Biol Chem. 2012 Dec 7;287(50):41914-21
pubmed: 23086940
Nucleic Acids Res. 2018 Jul 2;46(W1):W242-W245
pubmed: 29762716
Curr Protoc. 2021 Mar;1(3):e90
pubmed: 33780170
Nat Metab. 2021 Jul;3(7):883-886
pubmed: 34117483
Dis Model Mech. 2010 Sep-Oct;3(9-10):525-34
pubmed: 20713647
Cell Rep. 2017 Oct 24;21(4):1021-1035
pubmed: 29069585
Diabetes. 2013 Mar;62(3):837-44
pubmed: 23209190
Endocrinology. 2015 Nov;156(11):4020-32
pubmed: 26248218
J Clin Invest. 2016 Nov 1;126(11):4372-4386
pubmed: 27669460
Nat Commun. 2013;4:1528
pubmed: 23443556
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Cell Rep. 2017 Oct 10;21(2):403-416
pubmed: 29020627
Cell Metab. 2013 Jan 8;17(1):141-52
pubmed: 23312289
Diabetologia. 2013 May;56(5):1129-39
pubmed: 23423668
J Biol Chem. 2004 Apr 9;279(15):15662-9
pubmed: 14742444
Nat Rev Endocrinol. 2021 May;17(5):276-295
pubmed: 33627836
N Engl J Med. 2009 Apr 9;360(15):1509-17
pubmed: 19357406

Auteurs

Emeline Recazens (E)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Geneviève Tavernier (G)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Jérémy Dufau (J)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Camille Bergoglio (C)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Fadila Benhamed (F)

University of Paris, Cochin Institute, CNRS, INSERM, Paris, France.

Stéphanie Cassant-Sourdy (S)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Marie-Adeline Marques (MA)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Sylvie Caspar-Bauguil (S)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.
Toulouse University Hospital Center, Biochemisty Laboratory, Toulouse, France.

Alice Brion (A)

Genome Structure and Instability Laboratory, INSERM, CNRS, National Museum of Natural History, Paris, France.

Laurent Monbrun (L)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Renaud Dentin (R)

University of Paris, Cochin Institute, CNRS, INSERM, Paris, France.

Clara Ferrier (C)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Mélanie Leroux (M)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Pierre-Damien Denechaud (PD)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Cedric Moro (C)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Jean-Paul Concordet (JP)

Genome Structure and Instability Laboratory, INSERM, CNRS, National Museum of Natural History, Paris, France.

Catherine Postic (C)

University of Paris, Cochin Institute, CNRS, INSERM, Paris, France.

Etienne Mouisel (E)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.

Dominique Langin (D)

Institute of Metabolic and Cardiovascular Diseases (I2MC), Equipe MetaDiab, University of Toulouse, INSERM, University of Toulouse III - Paul Sabatier (UPS), Toulouse, France.
Toulouse University Hospital Center, Biochemisty Laboratory, Toulouse, France.
Academic Institute of France (IUF), Paris, France.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH